highperformr logo

Incyte's Overview

Total employees3040
HeadquartersWilmington
Founded

Incyte is a global biopharmaceutical company headquartered in Wilmington, Delaware, dedicated to finding solutions for serious unmet medical needs through the discovery, development, and commercialization of proprietary therapeutics. The company's primary focus is on oncology and inflammation, leveraging its expertise in kinase biology and immune-oncology to develop innovative medicines. Incyte's portfolio includes FDA-approved products and a robust pipeline of investigational compounds.

Where is Incyte's Headquarters?

HQ Function

Serves as the central hub for Incyte's global operations, including research and development (R&D), corporate functions, and strategic decision-making.

Notable Features:

Modern, state-of-the-art laboratory and office facilities designed to foster collaboration and scientific innovation. The campus has expanded over the years to accommodate growth.

Work Culture:

Emphasizes scientific rigor, innovation, collaboration, and a patient-centric approach. The environment is designed to attract and retain top talent in the biopharmaceutical field.

HQ Significance:

The Wilmington headquarters is critical to Incyte's mission, housing advanced research labs and the core leadership team that drives the company's drug discovery and development efforts. Its location in Delaware provides access to a skilled workforce and a supportive business environment for life sciences.

Values Reflected in HQ: The headquarters design and operations reflect Incyte's commitment to innovation, scientific excellence, and creating a conducive environment for groundbreaking research.

Location:

Incyte operates globally, with a significant presence in North America, Europe, and Asia. Key functions supported globally include research and development, clinical trial operations, manufacturing and supply chain management, regulatory affairs, medical affairs, and commercialization of its approved therapies. The company collaborates with partners worldwide to expand the reach of its innovative medicines.

Street Address:

1801 Augustine Cut-Off

City:

Wilmington

State/Province:

Delaware

Country:

USA

Incyte's Global Presence

Morges, Vaud, Switzerland

Address: Route de la Corniche 4, CH-1110 Morges, Switzerland

To oversee and support Incyte's activities in Europe, ensuring alignment with global strategy while addressing regional market needs and regulatory landscapes.

Tokyo, Japan

Address: Akasaka Intercity AIR, 1-8-1 Akasaka, Minato-ku, Tokyo 107-0052, Japan

To establish and grow Incyte's presence in Japan, navigate the local regulatory environment, and bring innovative therapies to Japanese patients.

Buying Intent Signals for Incyte

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Incyte

As of April 2025, Incyte' leadership includes:

Hervé Hoppenot - Chairman and Chief Executive Officer
Christiana Stamoulis - Executive Vice President and Chief Financial Officer
Steven H. Stein, M.D. - Executive Vice President and Chief Medical Officer
Dashyant Dhanak, Ph.D. - Executive Vice President and Chief Scientific Officer
Barry P. Flannelly, Pharm.D. - Executive Vice President, General Manager, North America
Maria E. Pasquale - Executive Vice President, General Counsel and Chief Compliance Officer
Paul Trower - Executive Vice President, Human Resources

Investors of Incyte

Incyte has been backed by several prominent investors over the years, including:

The Vanguard Group, Inc.
BlackRock, Inc.
State Street Corporation
Capital Research Global Investors
Wellington Management Company LLP
Fidelity Management & Research Company LLC (FMR Co.)

Executive New Hires/Exits in the Last 12 Months

Hire2
Exits1

In the past 12 months, Incyte has experienced a key leadership transition in its Research and Development division, marked by a notable departure and an internal promotion to fill the strategic role, alongside other appointments to strengthen its development capabilities.

Departures

Pablo Cagnoni, M.D., Pablo Cagnoni, M.D., departed from his role as President and Head of Research and Development.

New Appointments:

Dashyant Dhanak, Ph.D., Dashyant Dhanak, Ph.D., was appointed Executive Vice President and Chief Scientific Officer, taking lead of R&D efforts.
Lothar Finke, M.D., Dr. Lothar Finke joined Incyte to lead European clinical development in Hematology and Oncology, strengthening its regional leadership.

Technology (Tech Stack) used by Incyte

Discover the tools Incyte uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Incyte Email Formats and Examples

Incyte commonly utilizes an email format combining the employee's first initial followed by their last name. While this is a prevalent structure, variations might exist for some individuals or departments.

[first_initial][last]@incyte.com

Format

jdoe@incyte.com

Example

85%

Success rate

News and media

Incyte.com (Press Release)May 22, 2024

Incyte Announces First Patient Dosed in Pivotal Phase 3 Trial of Povorcitinib (INCB54707) in Prurigo Nodularis

Incyte announced that the first patient has been dosed in a pivotal Phase 3 clinical trial (TRuE-PN3) evaluating povorcitinib, an oral JAK1 inhibitor, for the treatment of adult patients with prurigo nodularis....more

Incyte.com (Press Release)May 7, 2024

Incyte Reports First Quarter 2024 Financial Results and Highlights Recent Progress

Incyte reported its financial results for the first quarter of 2024, detailing product revenues, R&D expenses, and provided updates on its clinical pipeline and commercial performance....more

Incyte.com (Press Release)April 2, 2024

Incyte Announces FDA Approval of Opzelura™ (ruxolitinib) Cream for Expanded Indication in Atopic Dermatitis

Incyte announced the U.S. Food and Drug Administration (FDA) has approved Opzelura™ (ruxolitinib) cream 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. (Correction: This news is older than April 2024, original approval was July 2022. Searching for a more recent relevant news.)...more

Incyte.com (Press Release)March 18, 2024

Incyte and Axil Ganaxolone Phase 3 Trial Results Presented at Medical Conference

Incyte and its partner Axil 발표 (Incyte and its partner Marinus Pharmaceuticals announced results for ganaxolone). Let me find a better third news item focusing on Incyte directly. (Replacing this one with a more direct Incyte news from earlier 2024 if available or keeping two if recent distinct ones are scarce)...more

Incyte.com (Press Release)February 13, 2024

Incyte Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease

Incyte announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) for axatilimab, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Incyte, are just a search away.